Literature DB >> 28028751

Epigenetic Modification Mediates the Increase of LAG-3+ T Cells in Chronic Osteomyelitis.

Yicun Wang1, Jun Wang1, Jia Meng1, Hui Jiang1, Jianning Zhao1, Hongbo Qian2, Tao Chen3.   

Abstract

Immune suppression plays critical roles in the development of chronic osteomyelitis, and the mechanisms underlying the development of immune suppression in chronic osteomyelitis have attracted much attention. LAG-3 is an important suppressor of T cell activation, but the role of LAG-3 in the immune regulation of chronic osteomyelitis is currently unknown. We sought to demonstrate if LAG-3 plays crucial roles in chronic osteomyelitis progression and has effects on immune suppression and exhausting of T cells, and what is the mechanism underlying LAG-3 deregulation in chronic osteomyelitis. We examined the expression of LAG-3 in the T cells of peripheral blood of 50 healthy controls and 50 patients with chronic osteomyelitis by flow cytometry. Clinical data were analyzed to determine the correlation between inflammation index and LAG-3 expression. Moreover, we isolated the CD4+ T cells from healthy controls and chronic osteomyelitis patients to compare cell proliferation and IFN-γ production. Chromatin immunoprecipitation assays were utilized to analyze the epigenetic modification on LAG-3 expression in T cells. We found that LAG-3 was significantly increased in the T cells of peripheral blood from chronic osteomyelitis patients. Subsequently, clinical data analysis suggested that the higher expression of LAG-3 was associated with severer inflammation situation. Consistently, LAG-3+CD4+ T cells exhibited impaired cell proliferation and IFN-γ secretion. Deregulation of histone methylation mediated the increase of LAG-3+ T cells during chronic osteomyelitis. Taken together, our study demonstrates the increase of LAG-3+ T cells and its immune regulatory roles in chronic osteomyelitis progression, suggesting new mechanisms and potential therapeutic targets for chronic osteomyelitis.

Entities:  

Keywords:  LAG-3; T cells; chronic osteomyelitis; epigenetic modification

Mesh:

Substances:

Year:  2017        PMID: 28028751     DOI: 10.1007/s10753-016-0486-0

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  28 in total

Review 1.  Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature.

Authors:  Amy K Slenker; Scott W Keith; David L Horn
Journal:  Diagn Microbiol Infect Dis       Date:  2012-05       Impact factor: 2.803

Review 2.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

3.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

Review 5.  Osteomyelitis: a current challenge.

Authors:  Luciana Souza Jorge; Alceu Gomes Chueire; Andréa Regina Baptista Rossit
Journal:  Braz J Infect Dis       Date:  2010 May-Jun       Impact factor: 1.949

Review 6.  Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Authors:  Linh T Nguyen; Pamela S Ohashi
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

7.  TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses.

Authors:  Tomohisa Okamura; Shuji Sumitomo; Kaoru Morita; Yukiko Iwasaki; Mariko Inoue; Shinichiro Nakachi; Toshihiko Komai; Hirofumi Shoda; Jun-Ichi Miyazaki; Keishi Fujio; Kazuhiko Yamamoto
Journal:  Nat Commun       Date:  2015-02-19       Impact factor: 14.919

8.  T lymphocytes in implant-associated posttraumatic osteomyelitis: Identification of cytotoxic T effector cells at the site of infection.

Authors:  Christof Wagner; Dominik Heck; Karin Lautenschläger; Christof Iking-Konert; Volkmar Heppert; Andreas Wentzensen; Gertrud Maria Hänsch
Journal:  Shock       Date:  2006-03       Impact factor: 3.454

9.  Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients.

Authors:  Fu-Jun Li; Ying Zhang; Guang-Xin Jin; Lei Yao; De-Quan Wu
Journal:  Immunol Lett       Date:  2012-12-20       Impact factor: 3.685

10.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

View more
  3 in total

1.  Immunoregulatory role of IL-2/STAT5/CD4+CD25+Foxp3 Treg pathway in the pathogenesis of chronic osteomyelitis.

Authors:  Qi-Fen Mao; Zui-Fei Shang-Guan; Hong-Lei Chen; Kai Huang
Journal:  Ann Transl Med       Date:  2019-08

Review 2.  Chronic Implant-Related Bone Infections-Can Immune Modulation be a Therapeutic Strategy?

Authors:  Elisabeth Seebach; Katharina F Kubatzky
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

3.  Metatranscriptome sequencing identifies Escherichia are major contributors to pathogenic functions and biofilm formation in diabetes related foot osteomyelitis.

Authors:  Michael Radzieta; Matthew Malone; Mehtab Ahmad; Hugh G Dickson; Saskia Schwarzer; Slade O Jensen; Lawrence A Lavery
Journal:  Front Microbiol       Date:  2022-08-01       Impact factor: 6.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.